sglt2 inhibitors and cardiovascular outcomes in type 2 diabetes: vertis cv trial
Published 2 years ago • 92 plays • Length 7:14Download video MP4
Download video MP3
Similar videos
-
2:27
cardiovascular benefit with sglt2 inhibition
-
8:15
sglt2 inhibitors and heart failure
-
1:23:07
sglt2 inhibitors & cardiovascular outcome
-
6:57
how does dapagliflozin work? understanding sglt2 inhibitors.
-
10:37
cardiovascular outcomes in new users of sglt-2 inhibitors
-
0:30
sglt2 inhibitors for diabetics
-
2:09
is one sglt2 (or glp-1) just like another for cardiac benefit?
-
27:44
are there alternative mechanisms to explain sglt2i beneficial cveffects in some patients?
-
15:34
sglt2 inhibitors vs glp-1 agonists: a cardiologist and an endocrinologist weigh in
-
8:32
dr julie lovshin - sglt2i cardiorenal mechanisms in diabetes and beyond - summary presentation
-
52:01
cardiovascular risk reduction with sglt2 inhibitors and glpl agonists
-
1:06:15
a tale of salt and sugar: sglt2 inhibitors in cardiovascular disease
-
3:07
using glp-1 agonists & sglt-2 inhibitors together from the cardiologist's perspective (sglt2 & glp1)
-
14:53
fundamentals of sglt2i's and glp-1ra's for cv risk
-
25:32
dr julie lovshin - sglt2i cardiorenal mechanisms in diabetes and beyond - full presentation
-
22:15
sglt-2 inhibitors for type 2 diabetes - amel arnaout, md
-
1:44
sglt2 inhibitors mechanism of action
-
7:18
do sglt-2 inhibitors reduce risk of heart failure? doctors discuss sglt2 inhibitor empagliflozin.
-
1:03
sglt2 drugs: helping diabetics and their hearts.